Oncology · 3 h ago
Single-cell study maps clonal diversity in pancreatic cancer
Researchers analyzed gene activity in 443,451 cells from 62 pancreatic ductal adenocarcinoma tumors to investigate tumor diversity and evolution. Laboratory experiments found that blocking MYC shifted aggressive basal cancer cells toward a less aggressive classical state; the findings are preclinical and do not establish a treatment approach for patients.
- Single-cell analysis covered 443,451 cells from 62 tumors.
- Tumors contained approximately two to 11 distinct clones.
- MYC blockade shifted aggressive cells in laboratory experiments.
- Clinical benefit from targeting MYC was not established.
Researchers analyzed gene activity in 443,451 individual cells from 62 pancreatic ductal adenocarcinoma tumors collected from 56 patients. Six patients provided samples before and after chemotherapy. The study examined how distinct tumor cell clones and changes in gene activity relate to cancer progression, treatment resistance and spread.
Tumors contained approximately two to 11 distinct clones, with varying combinations of classical and basal cell states. Some clones showed increased MYC activity, while others had increased TIGIT and reduced PD1 activity. In laboratory experiments, blocking MYC in aggressive basal cancer cells shifted them toward the less aggressive classical state and made them more exposed to immune cells.
The findings offer a detailed view of tumor heterogeneity and suggest mechanisms that may contribute to immune evasion and treatment resistance. However, the MYC experiments were conducted in cells, and the study does not show that targeting MYC improves outcomes in patients. The source reports that clinical trials of MYC- or TIGIT-inhibiting drugs are underway, but provides no trial results. Larger studies are needed to assess the clinical relevance of these findings.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Genetics (via ScienceDaily): Scientists discover how pancreatic cancer rewrites its DNA to escape treatment ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.